## (Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical Pricing Authority

New Delhi, 18th April, 2022

## **ORDER**

S. O.1833(E):-In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30<sup>th</sup> May, 2013 and S. O. 701(E) dated 10<sup>th</sup> March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

## <u>Table</u>

SI. No.	Name of the Formulation / Brand	Strength	Unit	Manufacturer & Marketing	Retail Price
	Name			Company	(Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Metformin (extended-release) + Teneligliptin Tablet	Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 500mg (as Extended-Release) Teneligliptin Hydrobromide hydrate eq. to Teneligliptin 20mg	1 Tablet	M/s Associated Biotech / M/s Dales Laboratories	7.14
2.	Dapagliflozin + Metformin Hydrochloride Extended release Tablet	Each film-coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg, Metformin Hydrochloride IP 1000mg (As Extended release form)	1 Tablet	M/s Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited	10.70
3.	Dapagliflozin + Metformin Hydrochloride (As Extended release form) Tablet	Each film-coated bilayered tablet contains:  Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg, Metformin Hydrochloride IP 1000mg (As Extended release form)	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Natco Pharma Ltd.	7.97
4.	Dapagliflozin + Metformin Hydrochloride (As	Each film-coated bilayered tablet contains:  Dapagliflozin Propanediol	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Apex	

SI. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
	Extended release form) Tablet	Monohydrate eq. to Dapagliflozin 10mg, Metformin Hydrochloride IP 1000mg (As Extended release form)		Laboratories Private Limited	10.70
5.	Dapagliflozin + Metformin Hydrochloride Extended release Tablet	Each film-coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg, Metformin Hydrochloride IP 500mg (As Extended release form)	1 Tablet	M/s Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited	9.18
6.	Dapagliflozin + Metformin Hydrochloride (As Extended release form) Tablet	tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg, Metformin Hydrochloride IP 500mg (As Extended release form)	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Natco Pharma Ltd.	7.30
7.	Dapagliflozin + Metformin Hydrochloride (As Extended release form) Tablet	Each film-coated bilayer tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg, Metformin Hydrochloride IP 500mg (As extended release form)	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Apex Laboratories Private Limited	9.18
8.	Dapagliflozin + Metformin Hydrochloride Extended release Tablet	Each film-coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg, Metformin Hydrochloride IP 1000mg (As extended release form)	1 Tablet	M/s Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited	7.29
9.	Dapagliflozin + Metformin Hydrochloride Extended release Tablet	Each film-coated tablet contains: Dapagliflozin 5mg, Metformin Hydrochloride IP/USP 1000mg (As extended release form)	1 Tablet	M/s MSN Laboratories Pvt. Ltd. / M/s USV Limited	7.29
10.	Dapagliflozin + Metformin Hydrochloride Extended release Tablet	Each film-coated tablet contains: Dapagliflozin 5mg, Metformin Hydrochloride IP/USP 500mg (As extended release form)	1 Tablet	M/s MSN Laboratories Pvt. Ltd. / M/s USV Limited	6.16
11.	Human Normal Immunoglobulin for	<b>Each vial contains:</b> Total Protein 50 g/L,	Per 1 ml (for	M/s Intas Pharmaceuticals	

SI. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
	Intravenous use IP 5% (Ig M Enriched)	Immunoglobulin M 6g/L, Immunoglobulin A 6g/L, Immunoglobulin G 38g/L, Glucose Monohydrate (as stabilizer) 27.5g/L, Sodium Chloride 4.56g/L, Water for injection q. s. Distribution of Ig G subclass is approx. 62%IgG1,27%IgG2,1%IgG3, 10%IgG4	10 ml vial)	Ltd	177.85
12.	Medroxyprogestero ne Acetate sustained release Tablet	Each uncoated sustained release tablet contains: Medroxyprogesterone Acetate IP 30mg	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Serum Institute of India Pvt. Ltd.	14.04
13.	Medroxyprogestero ne Acetate SR Tablet	Each uncoated sustained release tablet contains: Medroxyprogesterone Acetate IP 30mg	1 Tablet	M/s Synokem Pharmaceuticals Limited / M/s Torrent Pharmaceuticals Ltd.	14.04
14.	Glycopyrrolate + Formoterol Fumarate + Budesonide Inhalation	Each actuation delivers: Glycopyrrolate IP 9mcg Formoterol Fumarate Dihydrate IP eq. to Formoterol Fumarate 4.8mcg Budesonide IP 160mcg	1 MDI	M/s Zydus Healthcare Ltd.	8.63
15.	Folic Acid, Pyridoxine Hydrochloride, Methylcobalamin & Vitamin D3 Tablet	Each uncoated mouth dissolving tablet contains: Folic Acid IP 5mg Pyridoxine Hydrochloride IP 3mg Methylcobalamin IP 1500mcg Vitamin D3 IP 1000 IU	1 tablet	M/s Unison Pharmaceuticals Pvt. Ltd.	6.70

## Note:

- (a) The manufacturer of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- (b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall

- issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/228/96/2022/F

F. No. 8(96)/2022/D.P./NPPA-Div.-II

(Prasenjit Das) Deputy Director